BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
BRIDGEWATER, N.J., May 01, 2018 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief Executive Officer of Insmed, will present at the Deutsche Bank 43rd Annual Health Care Conference in Boston, MA on Tuesday, May 8, 2018 at 4:10 p.m. EDT.
The presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical Company focused on the unmet needs of patients with rare diseases. The Company’s lead product candidate is ALIS, which is in late-state development for adult patients with treatment refractory NTM lung disease caused by MAC, which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.
Contact:
Blaine Davis
Insmed Incorporated
(908) 947-2841
[email protected]
